Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2026)

Vertex Pharmaceuticals has reported Long-Term Investments for 7 years, with the latest figure at $5.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 11.51% year-over-year to $5.7 billion; the trailing twelve-month figure through Mar 2026 stood at $5.7 billion (up 11.51% YoY), and the FY2025 full-year result was $5.7 billion, up 11.83% from the prior year.
• Long-Term Investments for Q1 2026 stood at $5.7 billion, up from $5.7 billion in the prior quarter.
• The five-year high for Long-Term Investments was $5.7 billion in Q1 2026, with the low at $112.2 million in Q4 2022.
• Average Long-Term Investments over 5 years is $3.8 billion, with a median of $4.5 billion recorded in 2024.
• Year-over-year, Long-Term Investments soared 2126.2% in 2023 and increased 11.51% in 2026.
• Tracing VRTX's Long-Term Investments over 5 years: stood at $112.2 million in 2022, then soared by 2126.2% to $2.5 billion in 2023, then jumped by 104.5% to $5.1 billion in 2024, then gained by 11.83% to $5.7 billion in 2025, then advanced by 0.66% to $5.7 billion in 2026.
• The last three Long-Term Investments figures came in at $5.7 billion (Q1 2026), $5.7 billion (Q4 2025), and $5.7 billion (Q3 2025), per Business Quant data.

Peer Comparison